Search | Clinical Trials Finder

Conditions: Diabete Type 2, Neuropathy, Painful
Interventions: INF® Therapy, NVIf; Other
Lead sponsor: Loma Linda University; Other
Eligibility: 35 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Low Back Pain, Migraine, Diabetic Neuropathies, Osteoarthritis
Interventions: OraVescent Fentanyl; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 38
States / cities: Calera, Alabama • Hoover, Alabama • Phoenix, Arizona + 29 more

Conditions: Sciatica, Radiculopathy
Interventions: epidural steroid injection, Sham epidural steroid injection, Gabapentin, Placebo gabapentin; Procedure · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 17 Years to 100 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: San Diego, California • Baltimore, Maryland • Bethesda, Maryland

Conditions: Diabetic Neuropathy, Pain, Peripheral Neuropathy
Interventions: Precision Spinal Cord Stimulation; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Painful Diabetic Neuropathy
Interventions: Oral dose CNTX-6016 or oral dose Placebo; Drug
Lead sponsor: Centrexion Therapeutics; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Acute Lymphoblastic Leukemia, Neuropathy, Neuropathic Pain
Interventions: gabapentin, placebo; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 1 Year to 18 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Diabetic Neuropathy
Interventions: DA-9801 300mg, DA-9801 600mg, DA-9801 900mg, Placebo; Drug
Lead sponsor: NeuroBo Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 14
States / cities: Lakewood, California • Walnut Creek, California • Milford, Connecticut + 10 more

Conditions: Painful Diabetic Peripheral Neuropathy
Interventions: pregabalin, placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 55
States / cities: Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more

Conditions: Peripheral Neuralgia, Peripheral Neuropathy, Chronic Pain
Interventions: Nalu Neurostimulation System for PNS, Conventional Medical Management; Device · Other
Lead sponsor: Nalu Medical, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 17
States / cities: Tucson, Arizona • Burbank, California • Thousand Oaks, California + 14 more

Conditions: Facet Joints; Degeneration, Neuropathy, Neuralgia
Interventions: Cryoablation under image guidance, MRI Seednet Cryotherapy System (Galil Medical); Procedure · Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections, Peripheral Nervous System Diseases, Pain
Interventions: Capsaicin Dermal Patch; Drug
Lead sponsor: NeurogesX; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 35
States / cities: Phoenix, Arizona • Berkeley, California • San Diego, California + 29 more

Conditions: Low Back Pain, Osteoarthritis, Neuropathic Pain
Interventions: EN3409; Drug
Lead sponsor: BioDelivery Sciences International; Industry
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 57
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 52 more

Conditions: Diabetic Neuropathy, Chemotherapy Induced Neuropathy, HIV Neuropathy, Trauma Induced Neuropathy
Interventions: Neuron012703 (Medical Food); Drug
Lead sponsor: Targeted Medical Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pain
Interventions: [S,S]-Reboxetine, Any; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 24
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 20 more

Conditions: HIV Infections, Peripheral Nervous System Disease
Interventions: Peptide T; Drug
Lead sponsor: Advanced Peptides; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 4
States / cities: Miami, Florida • New York, New York

Conditions: Postherpetic Neuralgia, Diabetic Neuropathy, Complex Regional Pain Syndrome, Carpal Tunnel Syndrome, HIV Neuropathy, Idiopathic Sensory Neuropathy, Peripheral Neuropathy
Interventions: Placebo Capsules + Placebo Patch, Placebo capsules + Lidoderm®, Gabapentin + Placebo, Gabapentin + Lidoderm®, Gabapentin 300 mg capsules 1800 mg/day + placebo patch, Gabapentin 1800 mg/day + Lidoderm patch; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 7
States / cities: Birmingham, Alabama • Hueytown, Alabama • Phoenix, Arizona + 4 more

Conditions: ALS, Autism Spectrum Disorder, Cancer, Spasticity, Muscle, Dyskinetic Syndrome, Epilepsy, Glaucoma, Huntington Disease, Inflammatory Bowel Disease (IBD), Multiple Sclerosis, Neuropathy, Opioid Use, Parkinson Disease, HIV/AIDS, Ptsd, Intractable Pain, Sickle Cell Disease, Terminal Illness
Interventions: Registry, PK microsampling of blood; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Pain, Anxiety, Depression, Sleeplessness
Interventions: Nu-V3; Device
Lead sponsor: Nu-Life Solutions; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Schaumburg, Illinois • Greenwood, Indiana

Conditions: Diabetes
Interventions: Lidoderm; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 4
States / cities: Birmingham, Alabama • Hueytown, Alabama • Jacksonville, Florida + 1 more

Conditions: Neuropathic Pain From Spinal Cord Injury, Diabetic Peripheral Neuropathy, Post Herpetic Pain
Interventions: Not listed
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Diabetic Peripheral Neuropathy
Interventions: Pregabalin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 29
States / cities: Hot Springs, Arkansas • La Jolla, California • Torrance, California + 19 more

Conditions: Chemotherapy-induced Neuropathy
Interventions: Photon stimulation, Placebo treatment; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 754 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Radiculopathy, Sciatica
Interventions: Nortriptyline, Morphine; Drug
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: 19 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neuropathic Pain, Reflex Sympathetic Dystrophy, Peripheral Neuropathy, Post-herpetic Neuralgia, Spinal Cord Injury, Multiple Sclerosis
Interventions: Mild dose cannabis, Low dose cannabis, Cannabis; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 70 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Sacramento, California

Search by objective public record fields.

Combined Circulatory and Dietary Interventions for Neuropathy

Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough Pain

Steroids Versus Gabapentin

Spinal Cord Stimulation for Painful Diabetic Neuropathy

Safety, Tolerability & Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects With PDN

Therapeutic Interventions For Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL)

Study of DA-9801 to Treat Diabetic Neuropathy

Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain

Clinical Study of a Micro-Implantable Pulse Generator for the Treatment of Peripheral Neuropathic Pain (COMFORT 2)

MRI-Guided Cryoablation to Alleviate Pain in Head, Neck and Spine

Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy

Long-term Open-Label Safety Study to Evaluate EN3409

A Clinical Outcomes Study to Measure Reduction in Pain and Numbness During Administration of an Amino Acid Formulation in Subjects Diagnosed With Peripheral Neuropathy

[S,S]-Reboxetine Long Term Safety Study In Chronic Painful Diabetic Peripheral Neuropathy.

Intranasal Peptide T in the Treatment of Painful Peripheral Neuropathy of AIDS

A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions

Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products

Phase II Trial of Nu-V3 Non-Invasive Nerve Stimulation Device for Chronic Pain, Anxiety, Depression, Sleeplessness

Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy

Validation Study of Neuropathic Pain

Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy

Characterization and Treatment of Chemotherapy Neuropathy

Pain Treatment for Sciatica

Effects of Vaporized Marijuana on Neuropathic Pain